Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19-BCMA UCAR-T cell injection
- Development stage
- Unknown
- Lead developer
- iCell Gene Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD19-BCMA UCAR-T cell injection is an allogeneic, "off-the-shelf" chimeric antigen receptor (CAR) T-cell therapy designed to simultaneously target B-cell maturation antigen (BCMA) and CD19. Developed by Zhongshan People's Hospital, this dual-targeting approach aims to overcome antigen escape and improve efficacy in patients with relapsed or refractory multiple myeloma. As a universal CAR-T (UCAR-T) product, it is derived from healthy donor T-cells and engineered to minimize graft-versus-host disease (GvHD) and host-versus-graft (HvG) rejection, allowing for immediate availability without the need for patient-specific manufacturing. The therapy is currently being evaluated in clinical trials for its safety, tolerability, and preliminary antitumor activity.
- Other names
- CD19-BCMA UCAR-TCD-19-BCMA UCAR-TCD 19-BCMA UCAR-T
02
Targets
CD19 (B lymphocyte antigen CD19)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on CD19-BCMA UCAR-T cell injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19-BCMA UCAR-T cell injection.